HCPCS Code Applications and Approvals: July 2024
Quarterly archive · CMS Level II HCPCS54 coding decisions took effect July 1, 2024
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the First Quarter 2024 coding cycle, which took effect July 1, 2024.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
July 2024
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| C9113 | Pantoprazole Sodium Injection, pantoprazole sodium, per vial | — | Replaced byJ2470 | Discontinue | |
| C9168 | OMVOH Injection, mirikizumab-mrkz, 1 mg | ADVI Health, Eli Lilly and Company Intravenous/Subcutaneous | Replaced byJ2267 | Discontinue | |
| J0211 | Sodium Nitrite 3 Mg and Sodium Thiosulfate 125 Mg (Nithiodote) Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote) | — | — | Establish | |
| J0401 | ABILIFY MAINTENA Injection, aripiprazole (abilify maintena), 1 mg | Otsuka America Pharmaceutical, Inc. | — | Revise | |
| J0687 | Cefazolin Sodium (Wg Critical Care) Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | — | — | Establish | |
| J0872 | Daptomycin for Injection (room temperature) 505(b)(2) Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg | Xellia Pharmaceuticals USA, LLC Intravenous | — | Establish | |
| J0873 | Daptomycin for Injection (refrigerated) 505(b)(2) Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg | Xellia Pharmaceuticals USA, LLC | — | Revise | |
| J0911 | DEFENCATH Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis) | CorMedix | — | Establish | |
| J1597 | Glycopyrrolate (Glyrx-Pf) Injection, glycopyrrolate (glyrx-pf), 0.1 mg | — | — | Establish | |
| J1598 | Glycopyrrolate (Fresenius Kabi) Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to J1596, 0.1 mg | — | — | Establish | |
| J1748 | ZYMFENTRA Injection, infliximab-dyyb (zymfentra), 10 mg | Celltrion USA, Inc. Intravenous | — | Establish | |
| J2183 | Meropenem (Wg Critical Care) Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg | — | — | Establish | |
| J2246 | Baxter's Micafungin in Sodium Chloride Injection 505(b)(2) Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg | Baxter Healthcare Corporation (Baxter) Intravenous | — | Establish | |
| J2267 | OMVOH Injection, mirikizumab-mrkz, 1 mg | ADVI Health, Eli Lilly and Company Intravenous/Subcutaneous | ReplacesC9168 | Establish | |
| J2373 | Phenylephrine Hydrochloride (Immphentiv) 505(b)(2) Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms | — | — | Establish | |
| J2468 | Palonosetron Hydrochloride Injection 505(b)(2) Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to J2469, 25 micrograms | Avyxa Pharma | — | Establish | |
| J2470 | Pantoprazole Sodium 505(b)(2) Injection, pantoprazole sodium, 40 mg | — | ReplacesC9113 | Establish | |
| J2471 | Pantoprazole (Hikma) Injection, pantoprazole (hikma), not therapeutically equivalent to J2470, 40 mg | — | — | Establish | |
| J2780 | Ranitidine Injection, ranitidine hydrochloride, 25 mg | — | — | Discontinue | |
| J3247 | COSENTYX Injection, secukinumab, intravenous, 1 mg | Novartis Pharmaceuticals Corporation Intravenous | — | Establish | |
| J3263 | LOQTORZI Injection, toripalimab-tpzi, 1 mg | Coherus BioSciences Intravenous | — | Establish | |
| J3393 | ZYNTEGLO Injection, betibeglogene autotemcel, per treatment | bluebird bio, Inc. (bluebird) Intravenous | — | Establish | |
| J3394 | LYFGENIA Injection, lovotibeglogene autotemcel, per treatment | bluebird bio, Inc. (bluebird) Intravenous | — | Establish | |
| J7171 | ADZYNMA Injection, adamts13, recombinant-krhn, 10 iu | Takeda Pharmaceuticals America, Inc. Intravenous | — | Establish | |
| J7355 | iDose TR 505(b)(2) Injection, travoprost, intracameral implant, 1 microgram | Glaukos Intracameral | — | Establish | |
| J8611 | Methotrexate (Jylamvo) 505(b)(2) Methotrexate (jylamvo), oral, 2.5 mg | — | — | Establish | |
| J8612 | Methotrexate (Xatmep) 505(b)(2) Methotrexate (xatmep), oral, 2.5 mg | — | — | Establish | |
| J9361 | Ryzneuta Injection, efbemalenograstim alfa-vuxw, 0.5 mg | Acrotech Biopharma Subcutaneous | — | Establish | |
| J9371 | Vincristine Sulfate Liposome Injection, vincristine sulfate liposome, 1 mg | — | — | Discontinue | |
| Q4210 | Axolotl DualGraft & Axolotl Graft Axolotl graft or Axolotl dualgraft, per square centimeter | — | — | Discontinue | |
| Q4277 | WoundPlus Woundplus or e-graft, per square centimeter | Skye Biologics Holdings | Replaced byQ4326 | Discontinue | |
| Q4311 | Acesso Acesso, per square centimeter | Dynamic Medical Services LLC | — | Establish | |
| Q4312 | Acesso AC Acesso ac, per square centimeter | Dynamic Medical Services LLC | — | Establish | |
| Q4313 | DermaBind FM Dermabind fm, per square centimeter | HealthTech WC | — | Establish | |
| Q4314 | Reeva FT Reeva ft, per square centimeter | Legacy Medical Consultants | — | Establish | |
| Q4315 | RegeneLink Amniotic Membrane Allograft Regenelink amniotic membrane allograft, per square centimeter | LifeLink Foundation, Inc. | — | Establish | |
| Q4316 | AmchoPlast Amchoplast, per square centimeter | RMBB Health | — | Establish | |
| Q4317 | VitoGraft Vitograft, per square centimeter | Surgenex | — | Establish | |
| Q4318 | E-Graft E-graft, per square centimeter | Skye Biologics Holdings | — | Establish | |
| Q4320 | PelloGraft Pellograft, per square centimeter | Surgenex | — | Establish | |
| Q4321 | RenoGraft Renograft, per square centimeter | Surgenex | — | Establish | |
| Q4322 | CaregraFT Caregraft, per square centimeter | RegenTX Partners LLC | — | Establish | |
| Q4324 | AmnioTX Amniotx, per square centimeter | RegenTX Partners LLC | — | Establish | |
| Q4325 | ACApatch Acapatch, per square centimeter | RegenTX Partners LLC | — | Establish | |
| Q4326 | WoundPlus Woundplus, per square centimeter | Skye Biologics Holdings | ReplacesQ4277 | Establish | |
| Q4327 | DuoAmnion Duoamnion, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q4328 | MOST Most, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q4329 | Singlay Singlay, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q4330 | TOTAL Total, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q4331 | Axolotl DualGraft & Axolotl Graft Axolotl graft, per square centimeter | — | — | Establish | |
| Q4332 | Axolotl DualGraft & Axolotl Graft Axolotl dualgraft, per square centimeter | — | — | Establish | |
| Q4333 | ArdeoGraft Ardeograft, per square centimeter | Surgenex | — | Establish | |
| Q5137 | WEZLANA (SC) Biosimilar Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg | Amgen Subcutaneous/Intravenous | — | Establish | |
| Q5138 | WEZLANA (IV) Biosimilar Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg | Amgen Intravenous/Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, First Quarter 2024 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
